It was a bumpy start. A little over a year ago, on February 9, 2016, Brain, a small biotech company from Zwingenberg in the western German state of Hesse, went public on the Frankfurt stock exchange. But the move ended in success: Investors who bought shares at the time have been rewarded. The stock has gone from an issue price of €9 to €15.20 today. That’s a 70 percent gain.
Brain operates in the growth market of industrial biotechnology. The company sells enzymes and other microorganisms to industry, for uses in, for example, the production of bioethanol, the fuel derived from biomass. Brain’s products also extend the shelf life of food products and make laundry detergent clean more effectively at lower temperatures.
It is a growth industry: According to industry forecasts, the share of biotech products in the chemical industry is likely to double, to 20 percent, by 2020.